These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14711558)

  • 1. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis.
    Matsuo H
    Fertil Steril; 2004 Jan; 81(1):149-53. PubMed ID: 14711558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
    Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
    Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
    Surrey ES; Judd HL
    J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate.
    Makita K; Ishitani K; Ohta H; Horiguchi F; Nozawa S
    J Bone Miner Metab; 2005; 23(5):389-94. PubMed ID: 16133689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy.
    Stroup GB; Hoffman SJ; Vasko-Moser JA; Lechowska BA; Jenkins EL; Dare LC; Gowen M
    Bone; 2001 May; 28(5):532-7. PubMed ID: 11344053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
    Divasta AD; Laufer MR; Gordon CM
    J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists.
    Gnoth CH; Gödtke K; Freundl G; Godehardt E; Kienle E
    Gynecol Obstet Invest; 1999; 47(1):37-41. PubMed ID: 9852390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.
    Sagsveen M; Farmer JE; Prentice A; Breeze A
    Cochrane Database Syst Rev; 2003; 2003(4):CD001297. PubMed ID: 14583930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.
    Pierce SJ; Gazvani MR; Farquharson RG
    Fertil Steril; 2000 Nov; 74(5):964-8. PubMed ID: 11056241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
    Surrey ES; Voigt B; Fournet N; Judd HL
    Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
    Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
    Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of bone mineral density with vitamin D and estrogen receptor gene polymorphisms during GnRH agonist treatment.
    Seko M; Takeuchi H; Kinoshita K; Tokita A
    J Obstet Gynaecol Res; 2004 Apr; 30(2):130-5. PubMed ID: 15009617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-course of vertebral and femoral bone loss in rats administered gonadotrophin-releasing hormone agonist.
    Kurabayashi T; Fujimaki T; Yasuda M; Yamamoto Y; Tanaka K
    J Endocrinol; 1993 Jul; 138(1):115-25. PubMed ID: 7852882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
    Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
    J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover.
    Uemura H; Yasui T; Umino Y; Niki H; Takikawa M; Saito S; Furumoto H; Irahara M
    Bone; 2003 Nov; 33(5):860-6. PubMed ID: 14623063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment.
    Mukherjee T; Barad D; Turk R; Freeman R
    Am J Obstet Gynecol; 1996 Jul; 175(1):105-9. PubMed ID: 8694034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
    Taga M; Minaguchi H
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist.
    Assa A; Weiss M; Aharoni D; Mor A; Rachmiel M; Bistritzer T
    J Pediatr Endocrinol Metab; 2011; 24(7-8):505-10. PubMed ID: 21932589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
    Marshall LA; Cain DF; Dmowski WP; Chesnut CH
    Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.